Jefferies cut its price target on Hold-rated Pluristem Therapeutics (NASDAQ: PSTI) from $3.50 to $3 after the FDA has placed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE